Table 3.
Response to second-line chemotherapy according to pathology and regime.
| Histology | Chemo | CR | PR | SD | PD | NA |
|---|---|---|---|---|---|---|
| Synovial | Dox | 1 (0.3%) | 3 (0.8%) | 1 (0.3%) | ||
| Ifos | 1 (0.3%) | 4 (1.1%) | 2 (0.5%) | 15 (4.0%) | 1 (0.3%) | |
| Dox/Ifos | 1 (0.3%) | 2 (0.5%) | 1 (0.3%) | 2 (0.5%) | ||
| Other | 2 (0.5%) | 4 (1.1%) | 13 (3.4%) | |||
|
| ||||||
| Liposarcoma | Dox | 1 (0.3%) | 1 (0.3%) | 3 (0.8%) | 2 (0.5%) | |
| Ifos | 2 (0.5%) | 3 (0.8%) | 14 (3.7%) | |||
| Dox/Ifos | 5 (1.3%) | 1 (0.3%) | ||||
| Other | 1 (0.3%) | 5 (1.3%) | 6 (1.6%) | |||
|
| ||||||
| Leiomyosarcoma | Dox | 1 (0.3%) | 7 (1.8%) | 12 (3.2%) | 1 (0.3%) | |
| Ifos | 1 (0.3%) | 4 (1.1%) | 27 (7.1%) | 2 (0.5%) | ||
| Dox/Ifos | 1 (0.3%) | 2 (0.5%) | ||||
| Other | 2 (0.5%) | 14 (3.7%) | 59 (15.6%) | |||
|
| ||||||
| Other: | Dox | 6 (1.6%) | 23 (6.1%) | |||
| Ifos | 1 (0.3%) | 2 (0.5%) | 11 (2.9%) | 31 (8.2%) | 2 (0.5%) | |
| Dox/Ifos | 6 (1.6%) | |||||
| Other | 2 (0.5%) | 2 (0.5%) | 11 (2.9%) | 50 (13.2%) | 2 (0.5%) | |
Dox: doxorubicin, Ifos: Ifosfamide, CR: complete response, PR: partial response, SD: stable disease, PD: progressive disease, NA: not assessable.